The Lancet Study Just Called Out PTSD and Anxiety Cannabis Treatments. Here’s What It Means for Midwest Patients Specifically.

A veteran in Flint with a PTSD card. A teacher in Columbus certified for anxiety. A Minneapolis woman using cannabis for depression after cycling through four antidepressants. These are not edge cases in Midwest medical cannabis programs — they are the center of the market.

Which is why a systematic review published in Lancet Psychiatry this month has landed with unusual weight in the region. The study, drawing on 54 randomized controlled trials and nearly 2,500 participants over 45 years of research, reached a stark conclusion: there is “no significant” evidence that cannabinoids work for PTSD, anxiety, or depression.

Three of the top qualifying conditions in almost every Midwest medical program. One systematic review. A lot of uncomfortable questions.

What the Study Actually Found

Before getting to what it means state by state, it’s worth being precise about what the Lancet review did and didn’t say.

Researchers analyzed RCT data — the gold standard of clinical evidence — across a wide range of mental health conditions. Their central finding: cannabinoids showed “no significant effects” on outcomes for anxiety, PTSD, anorexia, psychotic disorders, and opioid use disorder. They also found, elsewhere in the data, limited evidence of harm.

The lead author stated plainly that they “found no evidence any form of cannabis is effective in treating anxiety, depression or post-traumatic stress disorder.”

This doesn’t mean cannabis does nothing for the people using it. RCTs measure population-level averages; they don’t negate individual experience. And cannabis research has been hampered for decades by federal prohibition, which has blocked large-scale trials and limited study design. What the Lancet review reflects is not a verdict on the therapeutic value of cannabis but on the current state of scientific evidence — which, after 45 years, remains inconclusive for the conditions most Midwest patients are certified under.

That distinction matters. But it doesn’t make the study easier to sit with.

Illinois: Conservative by Design, Exposed Anyway

Illinois is one of the more medically conservative states in the Midwest — notably, anxiety disorder is not a qualifying condition under the Illinois Department of Public Health’s program. The state has historically required a diagnosed debilitating condition with clinical documentation, and its condition review process is more formal than many peers.

But PTSD is on the Illinois qualifying list, and it’s one of the program’s most-used certifications. The IDPH maintains a formal process for reviewing conditions when new evidence emerges — a process that was designed precisely for moments like this.

Whether the department will act on the Lancet review is unclear. A spokesperson did not respond to request for comment before publication. But Illinois advocates and certifying physicians should expect questions from patients who’ve now seen this study in their news feeds. Those conversations are already happening in dispensaries and telehealth waiting rooms.

Michigan: The Biggest Exposure in the Region

Michigan has the most to reckon with. The state’s Bureau of Marihuana Regulation oversees a medical program that, as of the most recent public data, has issued more than 400,000 patient registrations — one of the largest active medical programs in the country.

Critically, Michigan’s qualifying conditions include both PTSD and anxiety disorders, making it the highest-exposure state in the Midwest under the Lancet findings. The volume is significant: anxiety and mental health conditions together represent a substantial portion of new certifications, particularly among patients who sought medical cards during the pandemic years when mental health diagnoses spiked.

Michigan’s LARA has not issued any statement in response to the review. Under current program rules, certification decisions remain with licensed physicians, and there is no automatic mechanism that would invalidate existing patient certifications based on new research.

Still, the state’s medical program structure invites a harder look at oversight: Are certifying physicians discussing current evidence with patients? Is informed consent in the certification process adequate?

Ohio: New Adult Market, Aging Medical Framework

Ohio legalized adult-use cannabis in 2023 and launched its retail market last year, which has drawn most of the policy attention in Columbus. But the state’s medical program — run through the Ohio Board of Pharmacy and the State Medical Board — remains active and hasn’t been structurally updated in several years.

PTSD is a qualifying condition in Ohio. Anxiety disorders are not, in a legal classification that mirrors Illinois. But that hasn’t stopped patients from obtaining certifications that reference anxiety-adjacent diagnoses under the program’s allowable conditions.

The Ohio Board of Pharmacy’s most recently published patient data showed over 107,000 registered patients, with chronic pain and PTSD among the most common qualifying conditions. The scale is smaller than Michigan, but the policy infrastructure is notably less agile. A formal process for re-evaluating qualifying conditions based on new research doesn’t appear prominently in the Ohio program’s public documentation.

Minnesota: Early Market, Watchful Moment

Minnesota launched its adult-use market in 2024 — later than many Midwest peers — and is still building out its regulatory architecture. Its medical program, historically one of the more restrictive in the region, has expanded qualifying conditions in recent years under pressure from patient advocates.

PTSD was added to Minnesota’s list after years of advocacy, particularly from veterans’ groups. Mental health conditions more broadly are now part of the program’s framework.

The state is in a formative period: its Office of Cannabis Management is writing and revising rules, and the Lancet findings arrive at a moment when the program’s clinical standards are still being shaped. How the OCM incorporates new evidence into its ongoing rulemaking is worth watching.

The Gap the Science Can’t Close — Yet

Here’s what every program administrator, certifying physician, and patient advocate should be honest about: this gap has always been there. State medical cannabis programs were not built on the same evidence base as FDA drug approvals. They were built on patient testimony, political will, and the reasonable argument that prohibition had blocked the research that would otherwise exist.

That argument is still valid. Federal prohibition remains in place. The DEA’s recent rescheduling action moved cannabis to Schedule III but did not open the research floodgates overnight. The Lancet review’s 54 RCTs are, in many ways, the ceiling of what researchers have been allowed to build.

Patients in Illinois, Michigan, Ohio, Minnesota, and Missouri didn’t get their certifications fraudulently. They were certified by licensed physicians, under rules their state legislatures enacted. The research not being there is a failure of federal policy, not of the patients themselves.

“The people in my waiting room who use cannabis for PTSD are not doing it recreationally,” one Chicago-area clinician told me, speaking on background. “They’re doing it because something else didn’t work, or they couldn’t access it, or the side effects were worse. That’s a real conversation. The Lancet study is part of it, but it’s not the end of it.”

What Should Actually Happen

State programs in the Midwest don’t need to strip cards. That would be logistically chaotic and ethically fraught — patients have made medical and financial decisions based on lawful access they were granted.

What should happen:

– Certifying physicians should be discussing the current state of evidence with patients at renewal, not just at initial certification. – State health departments with formal condition-review processes (Illinois, Ohio) should initiate a review of the relevant qualifying conditions and publish their findings, even if the result is “condition retained pending further research.” – Michigan’s LARA should conduct outreach to the certifying physician community on evidence standards. – Minnesota’s Office of Cannabis Management should incorporate the Lancet review into its ongoing rulemaking process.

None of that is politically easy. All of it is the job.

The Lancet study isn’t a weapon — it’s a dataset. Midwest programs that have been outrunning the evidence should use this moment to close that gap, not pretend the review didn’t happen, and not overcorrect in ways that abandon patients who have real relief, even if that relief isn’t yet clinically explained.

That’s a tougher needle to thread. It’s also the honest one.

Marcus Okafor covers the Midwest for CannabisInquirer.com. He is based in Chicago.